Guangfu Hu1, Wei Zhu2, Weige Yang3, Hong Wang4, Lei Shen5, Hongwei Zhang6. 1. Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. hu.guangfu@zs-hospital.sh.cn. 2. Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zhu.wei1@zs-hospital.sh.cn. 3. Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. yang.weige@zs-hospital.sh.cn. 4. Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. wang.hong@zs-hospital.sh.cn. 5. Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. 146381536@qq.com. 6. Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zhang.hongwei@zs-hospital.sh.cn.
Abstract
BACKGROUND: This systematic review and meta-analysis aimed to evaluate the effectiveness of radioactive iodine (RAI) remnant ablation for thyroid cancer-related outcomes of patients with papillary thyroid microcarcinoma (PTMC). METHODS: A systematic literature search of PubMed, EMBASE OvidSP, and EBSCO was conducted. Studies were selected that provided multivariable analysis of the effectiveness of RAI ablation or provided specific data of a 10 years history of thyroid cancer-related outcomes in patients that presented with PTMC. RESULTS: Nineteen studies met the inclusion criteria. A multivariable analysis of the effectiveness of RAI ablation for any recurrence or thyroid cancer-related mortality in patients with PTMC was performed in several studies, among which only one study reported a positive result. Furthermore, for PTMC patients treated by total or near-total thyroidectomy (TT/NT), with or without RAI ablative therapy, the meta-analysis suggested that RAI ablation did not decrease the 10 years history of any tumor recurrence (relative risk [RR] 0.96; 95% confidence interval [CI] 0.63-1.48; P = 0.87), locoregional recurrence (RR 1.15; 95% CI 0.75-1.76; P = 0.51), distant metastases (RR 0.32; 95% CI 0.08-1.32; P = 0.11) or thyroid cancer-related mortality (RR 0.76; 95% CI 0.22-2.63; P = 0.66). CONCLUSIONS: With regard to multivariable analyses, there was almost no positive treatment effect of RAI ablation noted for patients with PTMC. For PTMC patients already treated by TT/NT, incremental RAI ablation may not be beneficial at decreasing the 10 years recurrence of PTMC or incidence of thyroid cancer-related mortality.
BACKGROUND: This systematic review and meta-analysis aimed to evaluate the effectiveness of radioactive iodine (RAI) remnant ablation for thyroid cancer-related outcomes of patients with papillary thyroid microcarcinoma (PTMC). METHODS: A systematic literature search of PubMed, EMBASE OvidSP, and EBSCO was conducted. Studies were selected that provided multivariable analysis of the effectiveness of RAI ablation or provided specific data of a 10 years history of thyroid cancer-related outcomes in patients that presented with PTMC. RESULTS: Nineteen studies met the inclusion criteria. A multivariable analysis of the effectiveness of RAI ablation for any recurrence or thyroid cancer-related mortality in patients with PTMC was performed in several studies, among which only one study reported a positive result. Furthermore, for PTMC patients treated by total or near-total thyroidectomy (TT/NT), with or without RAI ablative therapy, the meta-analysis suggested that RAI ablation did not decrease the 10 years history of any tumor recurrence (relative risk [RR] 0.96; 95% confidence interval [CI] 0.63-1.48; P = 0.87), locoregional recurrence (RR 1.15; 95% CI 0.75-1.76; P = 0.51), distant metastases (RR 0.32; 95% CI 0.08-1.32; P = 0.11) or thyroid cancer-related mortality (RR 0.76; 95% CI 0.22-2.63; P = 0.66). CONCLUSIONS: With regard to multivariable analyses, there was almost no positive treatment effect of RAI ablation noted for patients with PTMC. For PTMC patients already treated by TT/NT, incremental RAI ablation may not be beneficial at decreasing the 10 years recurrence of PTMC or incidence of thyroid cancer-related mortality.
Authors: E Baudin; J P Travagli; J Ropers; F Mancusi; G Bruno-Bossio; B Caillou; A F Cailleux; J D Lumbroso; C Parmentier; M Schlumberger Journal: Cancer Date: 1998-08-01 Impact factor: 6.860
Authors: Nimmi Arora; Harma K Turbendian; Meredith A Kato; Tracy A Moo; Rasa Zarnegar; Thomas J Fahey Journal: Thyroid Date: 2009-05 Impact factor: 6.568
Authors: Elio Roti; Roberta Rossi; Giorgio Trasforini; Fiorenza Bertelli; Maria Rosaria Ambrosio; Luciano Busutti; Elizabeth N Pearce; Lewis E Braverman; Ettore C Degli Uberti Journal: J Clin Endocrinol Metab Date: 2006-02-14 Impact factor: 5.958
Authors: Dessislava I Stefanova; Arpita Bose; Timothy M Ullmann; Jessica N Limberg; Brendan M Finnerty; Rasa Zarnegar; Thomas J Fahey; Toni Beninato Journal: World J Surg Date: 2020-02 Impact factor: 3.352
Authors: Juan J Díez; Emma Anda; Victoria Alcazar; María L Isidro; Cristina Familiar; Miguel Paja; Patricia Rojas Marcos; Begoña Pérez-Corral; Elena Navarro; Ana R Romero-Lluch; Amelia Oleaga; María J Pamplona; José C Fernández-García; Ana Megía; Laura Manjón; Cecilia Sánchez-Ragnarsson; Pedro Iglesias; Julia Sastre Journal: Endocrine Date: 2022-05-18 Impact factor: 3.925